Interestingly, a detailed single cell RNA-seq study using pre- and post-enzalutamide biopsies identified clonal expansion of T cells suggesting that response to enzalutamide (and tumour cell death) may be a pre-requisite for response to enzalutamide/anti-PD-L1/1 combination therapy (He et al. 2021). Here, CD274 is linked to neoplasm.